πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,432 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11498928

Macrocyclic spiroethers as Mcl-1 inhibitors

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11492349

IRAK inhibitors and method for making and using

Rigel Pharmaceuticals, Inc. Β· Granted Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11492351

MTA-cooperative PRMT5 inhibitors

Mirati Therapeutics, Inc. Β· Granted Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11485738

Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

Mirati Therapeutics, Inc. Β· Granted Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11485760

Inhibitors of CRISPR-Cas9

The Regents of the University of California Β· Granted Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11485739

Compounds useful as inhibitors of ATR kinase

Vertex Pharmaceuticals Incorporated Β· Granted Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11479551

MTA-cooperative PRMT5 inhibitors

Mirati Therapeutics, Inc. Β· Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11479770

Use of p38 inhibitors to reduce expression of DUX4

Fulcrum Therapeutics, Inc. Β· Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11479543

Heterocyclic RIP1 kinase inhibitors

Rigel Pharmaceuticals, Inc. Β· Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11471528

Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to

The Government of the United States of America as represented by the Secretary of the Department Β· Granted Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11466018

TGF-Ξ² inhibitors

Rigel Pharmaceuticals, Inc. Β· Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11465972

Inhibitors of oxidized low-density lipoprotein receptor 1 and methods of use thereof

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11466017

Heterocyclic inhibitors of PTPN11

The Board of Regents of the University of Texas System Β· Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11464774

Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors

Vertex Pharmaceuticals Incorporated Β· Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11464856

Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15

Julius-Maximilians-Universitat Wurzburg Β· Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11459308

Broad spectrum inhibitors of filoviruses

The Government of the United States, as represented by the Secretary of the Army Β· Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11459340

Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors

NIKANG THERAPEUTICS, INC. Β· Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11453683

KRas G12D inhibitors

Mirati Therapeutics, Inc. Β· Granted Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11453668

JAK inhibitors containing a 4-membered heterocyclic amide

Theravance Biopharma R&D IP, LLC Β· Granted Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11452780

Mtorc1 inhibitors

The Regents of the University of California Β· Granted Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11452714

Antibacterial agents including histidine kinase inhibitors

Regents of the University of Minnesota Β· Granted Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11439611

Administration of serine protease inhibitors to the stomach

The Regents of the University of California Β· Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11439641

Pyrimidine JAK inhibitors for the treatment of skin diseases

Theravance Biopharma R&D IP, LLC Β· Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11439629

Methods for the administration of certain VMAT2 inhibitors

Neurocrine Biosciences, Inc. Β· Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted